Dietary Conjugated Linoleic Acids Arrest Cell Cycle Progression and Prevent Ovarian Cancer Xenografts Growth Suggesting a Trans-10 Cis-12 Isoform Specific Activity — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Dietary Conjugated Linoleic Acids Arrest Cell Cycle Progression and Prevent Ovarian Cancer Xenografts Growth Suggesting a Trans-10 Cis-12 Isoform Specific Activity
Knight Cancer Research Institute, Oregon Health and Sciences University, Portland, USA
,
Knight Cancer Research Institute, Oregon Health and Sciences University, Portland, USA
,
Knight Cancer Research Institute, Oregon Health and Sciences University, Portland, USA
,
Knight Cancer Research Institute, Oregon Health and Sciences University, Portland, USA
,
Knight Cancer Research Institute, Oregon Health and Sciences University, Portland, USA
,
Rich Graviss Pvt. Ltd., India
,
Cytopathology Lab, Legacy Emanuel Hospital, Portland, USA
,
Knight Cancer Research Institute, Oregon Health and Sciences University, Portland, USA
,
Molecular and Medical Genetics, Oregon Health and Science University, Portland, USA
1 Knight Cancer Research Institute, Oregon Health and Sciences University, Portland, USA
2 Knight Cancer Research Institute, Oregon Health and Sciences University, Portland, USA
3 Knight Cancer Research Institute, Oregon Health and Sciences University, Portland, USA
4 Knight Cancer Research Institute, Oregon Health and Sciences University, Portland, USA
5 Knight Cancer Research Institute, Oregon Health and Sciences University, Portland, USA
6 Rich Graviss Pvt. Ltd., India
7 Cytopathology Lab, Legacy Emanuel Hospital, Portland, USA
8 Knight Cancer Research Institute, Oregon Health and Sciences University, Portland, USA
9 Molecular and Medical Genetics, Oregon Health and Science University, Portland, USA
Therapies for treating ovarian cancer (OvCa) successfully are largely inadequate. Alternative therapies and diet(s) with preventive potential to debilitated onset, and reduced OvCa tumor burden in situ , have not been systematically studied. Preventive role of conjugated linoleic acids (CLAs) ha s been reported in many other cancers. We report the first systematic in vitro and in vivo study modeling potential preventive mechanism(s) of CLA, an octadecadienolic fatty acid in clear cell OvCa cell line TOV -21G . We demonstrate that a dose and time-dependent down-regulation of cyclin E and A proteins (p < 0.05) by CLA (t10 , c12) was concomitant with cell cycle arrest of TOV -21G cell lines in S phase. To understand the molecular mechanism underlying CLA (t10 , c12) induced S phase arrest, levels of cell cycle regulatory proteins were determined by western blot analyses. Exposure to CLA (t10 , c12) increased p21 (CIP1/WAF1) , and p27 (KIP1) protein levels in a time and dose-dependent manner. Interestingly CLA (t10,c12) did not significantly affect protein levels of cyclin-dependent kinase (cdk) 2, and p53 , however, hyperphosphorylated form of pRb (p < 0.05) w as abro gated. Exposure to CLA (c9,t11) indicated a modest increase in p21 (CIP1/WAF1) and p27 (KIP1) levels, but changes in cyclin A and E levels were statistically insignificant. These results indicate that CLA (t10 , c12) mediated p27 (KIP1) upregulation and inhibition of hyperphosphorylation of ppRb may be the possible mechanism for the S phase arrest in TOV -21G cell line. Our in vivo data showed that CLA reduced the progression of TOV -21G xenografts by >50%. Together our results provide evidence of CLA exerted preventive effect on OvCa cell and tumor growth. Tumor growth arrest may be resultant from CLA (t10 , c12) mediated modulation of cell cycle arrest.
N. Howlader, et al., “Use of Imputed Population-Based Cancer Registry Data as a Method of Accounting for Missing Information: Application to Estrogen Receptor Status for Breast Cancer,” American Journal of Epidemiology, Vol. 176, No. 4, 2012, pp. 347-356. doi:10.1093/aje/kwr512
J. M. Genkinger, S. A. Smith-Warner, et al., “A Pooled Analysis of 12 Cohort Studies of Dietary Fat, Cholesterol and Egg Intake and Ovarian Cancer,” Cancer Causes Control, Vol. 17, No. 3, 2006, pp. 273-285. doi:10.1007/s10552-005-0455-7
S. C. Larsson, N. Orsini and A. Wolk, “Milk, Milk Products and Lactose Intake and Ovarian Cancer Risk: A Meta-Analysis of Epidemiological Studies,” International Journal of Cancer, Vol. 118, No. 2, 2006, pp. 431-441. doi:10.1002/ijc.21305
A. Bhattacharya, et al., “Biological Effects of Conjugated Linoleic Acids in Health and Disease,” Journal of Nutritional Biochemistry, Vol. 17, No. 12, 2006, pp. 789-810. doi:10.1016/j.jn utbio.2006.02.009
A. Kennedy, et al., “Antiobesity Mechanisms of Action of Conjugated Linoleic Acid,” Journal of Nutritional Biochemistry, Vol. 21, No. 3, 2010, pp. 171-179. doi:10.1016/j.jnutbio.2009.08.003
N. S. Kelley, N. E. Hubbard and K. L. Erickson, “Conjugated Linoleic Acid Isomers and Cancer,” Journal of Nutrition, Vol. 137, No. 12, 2007, pp. 2599-25607.
P. Thuillier, et al., “Activators of Peroxisome Proliferator-Activated Receptor-Alpha Partially Inhibit Mouse Skin Tumor Promotion,” Mol Carcinog,. Vol. 29, No. 3, 2000, pp. 134-142.
D. J. Slamon, et al., “Studies of the HER-2/Neu ProtoOncogene in Human Breast and Ovarian Cancer,” Science, Vol. 244, No. 4905, 1989, pp. 707-712. doi:10.1126/science.2470152
A. Bellacosa, et al., “Molecular Alterations of the AKT2 Oncogene in Ovarian and Breast Carcinomas,” International Journal of Cancer, Vol. 64, No. 4, 1995, pp. 280-285. doi:10.1002/ijc.2910640412
L. Shayesteh, et al., “PIK3CA Is Implicated as an Oncogene in Ovarian Cancer,” Nature Genetics, Vol. 21, No. 1, 1999, pp. 99-102. doi:10.1038/5042
M. L. McCoy, C. R. Mueller and C. D. Roskelley, “The Role of the Breast Cancer Susceptibility Gene 1, No. (BRCA1) in Sporadic Epithelial Ovarian Cancer,” Reproductive Biology and Endocrinology, Vol. 1, 2003, p. 72. doi:10.1186/1477-7827-1-72
P. Spellman, et al., “Integrated Genomic Analyses of Ovarian Carcinoma,” Nature, Vol. 474, No. 7353, 2011, pp. 609-615. doi:10.1038/nature10166
W. Z. Wysham, et al., “BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence,” PLoS One, Vol. 7, No. 1, 2012, p. e30042. doi:10.1371/journal.pone.0030042
E. E. Hoskins, et al., “Coordinate Regulation of Fanconi anemia Gene Expression Occurs through the Rb/E2F Pathway,” Oncogene, Vol. 27, No. 35, 2008, pp. 4798-4808. doi:10.1038/onc.2008.121
M. Tategu, et al., “Systems Biology-Based Identification of Crosstalk between E2F Transcription Factors and the Fanconi Anemia Pathway,” Gene Regul Syst Bio, Vol. 1, 2007, pp. 1-8.
B. Majumder, et al., “Conjugated Linoleic Acids, No. (CLAs) Regulate the Expression of Key Apoptotic Genes in Human Breast Cancer Cells,” FASEB Journal, Vol. 16, No. 11, 2002, pp. 1447-1449.
T. Pejovic, et al., “Cytogenetic Instability in Ovarian Epithelial Cells from Women at Risk of Ovarian Cancer,” Cancer Research, Vol. 66, No. 18, 2006, pp. 9017-9025. doi:10.1158/0008-5472.CAN-06-0222
H. S. Zhang, et al., “Exit from G1 and S Phase of the Cell Cycle Is Regulated by Repressor Complexes Containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF,” Cell, Vol. 101, No. 1, 2000, pp. 79-89. doi:10.1016/S0092-8674,No.00)80625-X
Y. Zhang, et al., “S-Phase Arrest and Apoptosis Induced in Normal Mammary Epithelial Cells by a Novel Retinoid,” Cancer Research, Vol. 60, No. 7, 2000, pp. 2025-2032.
N. Bendris, et al., “Cyclin A2 Mutagenesis Analysis: A New Insight into CDK Activation and Cellular Localization Requirements,” PLoS One, Vol. 6, No. 7, 2011, p. e22879. doi:10.1371/jou rnal.pone.0022879
T. Taniguchi, et al., “Disruption of the Fanconi AnemiaBRCA Pathway in Cisplatin-Sensitive Ovarian Tumors,” Nature Medicine, Vol. 9, No. 5, 2003, pp. 568-574. doi:10.1038/nm852
G. Pagano, “Mitomycin C and Diepoxybutane Action Mechanisms and FANCC Protein Functions: Further Insights into the Role for Oxidative Stress in Fanconi’s Anaemia Phenotype,” Carcinogenesis, Vol. 21, No. 5, 2000, pp. 1067-1068. doi:10.1093/carcin/21.5.1067
G. Pagano and H. Youssoufian, “Fanconi Anaemia Proteins: Major Roles in Cell Protection against Oxidative Damage,” Bioessays, Vol. 25, No. 6, 2003, pp. 589-595. doi:10.1002/bies.10283
J. Bloom and F. R. Cross, “Multiple Levels of Cyclin Specificity in Cell-Cycle Control,” Nature Reviews Molecular Cell Biology, Vol. 8, No. 2, 2007, pp. 149-160. doi:10.1038/nrm2105
D. Reimer, et al., “Expression of the E2F Family of Transcription Factors and Its Clinical Relevance in Ovarian Cancer,” Annals of the New York Academy of Sciences, Vol. 1091, 2006, pp. 270-281. doi:10.1196/annals.1378.073
K. H. Vousden and C. Prives, “Blinded by the Light: The Growing Complexity of p53,” Cell, Vol. 137, No. 3, 2009, pp. 413-431. doi:10.1016/j.cell.2009.04.037
M. A. Belury, Inhibition of Carcinogenesis by Conjugated Linoleic Acid: Potential Mechanisms of Action,” Journal of Nutrition, Vol. 132, No. 10, 2002, pp. 2995-2998.
M. M. Ip, et al., “The t10,c12 Isomer of Conjugated Linoleic Acid Stimulates Mammary Tumorigenesis in Transgenic Mice Over-Expressing erbB2 in the Mammary Epithelium,” Carcinogenesis, Vol. 28, No. 6, 2007, pp. 1269-1276. doi:10.1093/carcin/bgm018
J. Rajakangas, et al., “Adenoma Growth Stimulation by the Trans-10, Cis-12 Isomer of Conjugated Linoleic Acid, No. CLA) Is Associated with Changes in Mucosal NF-kappaB and Cyclin D1 Protein Levels in the Min Mouse,” Journal of Nutrition, Vol. 133, No. 6, 2003, pp. 1943-1948.
N. Presneau, et al., “Patterns of Expression of Chromosome 17 Genes in Primary Cultures of Normal Ovarian Surface Epithelia and Epithelial Ovarian Cancer Cell Lines,” Oncogene, Vol. 22, No. 10, 2003, pp. 1568-1579. doi:10.1038/sj.onc.1206219